Isavuconazole can require therapeutic drug monitoring.

We suggest collecting one blood sample just before the first maintenance dose to estimate the patient’s most likely kinetic profile using Desai et al.’s population-pharmacokinetic model.

If the kinetic profile is close to the profiles simulated with Desai et al.’s population-pharmacokinetic model, there is no need to perform therapeutic drug monitoring.

If the kinetic profile is outside the expected range, an individualized dose adjustment may be proposed (together with an estimation of the new kinetic profile). For these patients, we suggest screening cytochrome P450 3A4 and 3A5 genetic polymorphisms to explain these profiles.